Morning Overview on MSN
SciNeuro, Novartis strike $1.7B Alzheimer’s drug megadeal
Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious ...
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat ...
Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...
Pharmaceutical Technology on MSN
JPM26: SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody
"JPM26: SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody" was originally created and published by ...
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals ...
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said ...
As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.
Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss ...
Novartis has released an open letter addressed to the world’s governments, urging them to take action in addressing the ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren's disease, including phase III trials1Distinction expedites development and review of treatments for serious conditi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback